Results for tag: "Infantile Neuroaxonal Dystrophy Drug"

Infantile Neuroaxonal Dystrophy (INAD) is a rare, progressive neurological disorder that affects the central nervous system. It is characterized by the degeneration of nerve cells in the brain and spinal cord, leading to a wide range of physical and cognitive impairments. Treatment for INAD is limited, and there is currently no cure. However, there are a number of drugs available to help manage the symptoms of the disorder. These drugs include anticonvulsants, muscle relaxants, and anti-inflammatory medications. In addition, some drugs have been developed specifically for INAD, such as the enzyme replacement therapy, Elosulfase Alfa. The INAD drug market is a small but growing sector of the Central Nervous System Drugs market. Companies such as Sanofi, Pfizer, and Shire are leading the way in developing new treatments for INAD. Other companies, such as BioMarin Pharmaceuticals and Ultragenyx Pharmaceuticals, are also actively researching and developing new drugs for the disorder. Show Less Read more